[go: up one dir, main page]

MX2009011275A - Una composicion de microesferas biodegradables adecuadas para la liberacion controlada de peptido de control de la glucosa y formulacion de la misma. - Google Patents

Una composicion de microesferas biodegradables adecuadas para la liberacion controlada de peptido de control de la glucosa y formulacion de la misma.

Info

Publication number
MX2009011275A
MX2009011275A MX2009011275A MX2009011275A MX2009011275A MX 2009011275 A MX2009011275 A MX 2009011275A MX 2009011275 A MX2009011275 A MX 2009011275A MX 2009011275 A MX2009011275 A MX 2009011275A MX 2009011275 A MX2009011275 A MX 2009011275A
Authority
MX
Mexico
Prior art keywords
glucose
formulation
controlled release
composition suitable
microsphere composition
Prior art date
Application number
MX2009011275A
Other languages
English (en)
Inventor
Moohi Yoo
Tae Hyoung Kim
Soo Hyung Kang
Byong Moon Kim
Hyun Hee Kwak
Ghun Il Lee
Yong Man Park
Mi Kyung Son
Hi Chang Yang
Yoon Ji Kim
Sung Hee Lee
Original Assignee
Dong A Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A Pharm Co Ltd filed Critical Dong A Pharm Co Ltd
Publication of MX2009011275A publication Critical patent/MX2009011275A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen las microesferas biodegradables capaces de liberar un péptido regulador de la glucosa de una manera controlada, que comprende un portador polimérico biodegradable con el péptido regulador de la glucosa encapsulado en éste, y los métodos para la preparación de las mismas. Además, para asegurar la alta eficiencia de encapsulamiento y la alta estabilidad del fármaco encapsulado, las microesferas no muestran un efecto inicial rápida ni tampoco liberación incompleta, y permiten la liberación de orden cero de los fármacos en un periodo prolongado, mejorando de este modo el efecto terapéutico del fármaco.
MX2009011275A 2007-04-19 2008-04-18 Una composicion de microesferas biodegradables adecuadas para la liberacion controlada de peptido de control de la glucosa y formulacion de la misma. MX2009011275A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20070038467 2007-04-19
PCT/KR2008/002216 WO2008130158A1 (en) 2007-04-19 2008-04-18 A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof

Publications (1)

Publication Number Publication Date
MX2009011275A true MX2009011275A (es) 2009-11-02

Family

ID=39875642

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011275A MX2009011275A (es) 2007-04-19 2008-04-18 Una composicion de microesferas biodegradables adecuadas para la liberacion controlada de peptido de control de la glucosa y formulacion de la misma.

Country Status (14)

Country Link
US (1) US8282990B2 (es)
EP (1) EP2139458A4 (es)
JP (1) JP5302952B2 (es)
KR (2) KR101034888B1 (es)
CN (1) CN101657190B (es)
AU (1) AU2008241699B2 (es)
BR (1) BRPI0810140A2 (es)
CA (1) CA2683698C (es)
CO (1) CO6241098A2 (es)
IL (1) IL201523A0 (es)
MX (1) MX2009011275A (es)
NZ (1) NZ580700A (es)
RU (1) RU2422134C1 (es)
WO (1) WO2008130158A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010111617A2 (en) 2009-03-27 2010-09-30 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
WO2011032099A1 (en) 2009-09-11 2011-03-17 The Board Of Trustees Of The University Of Illinois Methods of treating diastolic dysfunction and related conditions
WO2011056572A1 (en) 2009-10-27 2011-05-12 The Board Of Trustees Of The University Of Illinois Methods of diagnosing diastolic dysfunction
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
IN2012DN06437A (es) 2010-01-27 2015-10-09 Univ Indiana Res & Tech Corp
WO2011116026A2 (en) 2010-03-15 2011-09-22 The Board Of Trustees Of The University Of Illinois Inhibitors of beta integrin-g protein alpha subunit binding interactions
CN103068842B (zh) 2010-06-16 2016-10-19 印第安纳大学研究及科技有限公司 对胰岛素受体具有高活性的单链胰岛素激动剂
CN102370624A (zh) * 2010-08-17 2012-03-14 东莞太力生物工程有限公司 Exendin-4缓释微球及其注射剂和该缓释微球的制备方法
WO2012029827A1 (ja) * 2010-09-02 2012-03-08 日本化薬株式会社 薬物－ブロックコポリマー複合体とそれを含有する医薬の製造方法
KR101785515B1 (ko) * 2010-11-08 2017-10-16 에스케이케미칼주식회사 올란자핀 함유 고분자 미립구를 유효성분으로 포함하는 약학적 조성물
KR20120048811A (ko) * 2010-11-08 2012-05-16 에스케이케미칼주식회사 아나스트로졸 함유 고분자 미립구를 유효성분으로 포함하는 약학적 조성물
US9029502B2 (en) 2010-12-20 2015-05-12 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
CN103458920B (zh) 2010-12-22 2016-07-06 印第安那大学科技研究公司 表现出gip受体活性的胰高血糖素类似物
US9156902B2 (en) 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
WO2013055791A1 (en) 2011-10-10 2013-04-18 The Regents Of The University Of Michigan Polymeric nanoparticles for ultrasound imaging and therapy
MX2014003579A (es) 2011-11-17 2015-04-10 Univ Indiana Res & Tech Corp Peptidos de la superfamilia de glucagon que presentan actividad del receptor de glucocorticoide.
US9573987B2 (en) 2011-12-20 2017-02-21 Indiana University Research And Technology Corporation CTP-based insulin analogs for treatment of diabetes
SG11201408347UA (en) 2012-06-14 2015-01-29 Ambrx Inc Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
HRP20180936T1 (hr) 2012-06-21 2018-12-14 Indiana University Research And Technology Corporation Analozi glukagona koji pokazuju aktivnost prema receptoru za gip
WO2013192129A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
CA2886228A1 (en) 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
US20160024169A1 (en) 2013-03-14 2016-01-28 Indiana University Research And Technology Corporation Insulin-incretin conjugates
KR101486132B1 (ko) * 2013-03-20 2015-01-23 씨제이헬스케어 주식회사 졸-겔 변환 특성을 갖는 고분자를 이용한 미립구의 제조방법 및 이로부터 제조된 미립구
US10189908B2 (en) 2014-02-05 2019-01-29 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
EP3206710B1 (en) 2014-09-24 2020-05-06 Indiana University Research & Technology Corporation Incretin-insulin conjugates
CN107683289B (zh) 2015-01-26 2021-08-06 芝加哥大学 IL13Rα2结合剂和其在癌症治疗中的用途
CN107835820B (zh) 2015-01-26 2021-10-15 芝加哥大学 识别癌症特异性IL13Rα2的CAR T细胞
US20180201937A1 (en) 2015-08-04 2018-07-19 The University Of Chicago Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6
ES2960753T3 (es) 2015-09-21 2024-03-06 Teva Pharmaceuticals Int Gmbh Formulaciones de olanzapina de liberación sostenida
KR101706254B1 (ko) * 2015-11-17 2017-02-13 주식회사 동일팜텍 생체조직 수복 또는 재생용 고분자 미세입자의 제조방법
US10406336B2 (en) 2016-08-03 2019-09-10 Neil S. Davey Adjustable rate drug delivery implantable device
EP3600258A1 (en) 2017-03-20 2020-02-05 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulaitons
EP3645002B1 (en) 2017-06-30 2024-10-30 Amgen Inc. Methods of treating heart failure with cardiac sarcomere activators
TN2020000015A1 (en) 2017-08-03 2021-10-04 Amgen Inc Interleukin-21 muteins and methods of treatment
CA3075046A1 (en) 2017-09-08 2019-03-14 Amgen Inc. Inhibitors of kras g12c and methods of using the same
MX2020002921A (es) 2017-09-18 2020-09-28 Univ California Anticuerpos para claudin6 y métodos para tratar el cáncer.
KR102047983B1 (ko) 2017-11-30 2019-11-22 주식회사 지투지바이오 안전성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법
JP7054954B2 (ja) * 2018-01-10 2022-04-15 ジー２ジーバイオ インコーポレイテッド コラーゲンペプチドを含有したポリカプロラクトン微粒球フィラーおよびその製造方法
CN111727197A (zh) 2018-01-12 2020-09-29 美国安进公司 抗pd-1抗体和治疗方法
KR102137786B1 (ko) * 2018-07-19 2020-07-24 주식회사 아울바이오 주사제용 미립구의 제조방법
RU2696773C1 (ru) * 2018-08-13 2019-08-06 Алексей Николаевич Осинцев Способ получения лекарственного препарата пептидной природы с контролируемым и последовательным высвобождением
US20200085776A1 (en) 2018-09-10 2020-03-19 Cardax, Inc. Methods of Reducing C-Reactive Protein and/or Treating Cardiovascular Disease
CN114206934A (zh) 2019-03-20 2022-03-18 加利福尼亚大学董事会 密封蛋白-6双特异性抗体
HUE070544T2 (hu) 2019-03-20 2025-06-28 Univ California Klaudin-6-ellenanyagok és hatóanyag-konjugátumok
CA3136496A1 (en) 2019-04-09 2020-10-15 The Board Of Trustees Of The University Of Illinois Drug adsorbed highly porous activated carbon for enhanced drug delivery
US20230190725A1 (en) 2019-04-29 2023-06-22 The Board Of Trustees Of The University Of Illinois Mek inhibitors for corneal scarring and neovascularization
JP2022530241A (ja) 2019-04-30 2022-06-28 インスチトゥート デ メディシーナ モリクラール ジョアン ロボ アントゥネス Ｃｄｋ阻害剤と組み合わせたｒａｎｋ経路阻害剤
AU2020303986A1 (en) 2019-06-24 2021-12-09 Amgen Inc. Inhibition of SIRP-gamma for cancer treatment
JP2022546700A (ja) 2019-08-30 2022-11-07 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル ミトコンドリア機能障害に関連する神経変性障害の治療のための銅－ａｔｓｍ
KR102583029B1 (ko) * 2020-05-28 2023-09-26 주식회사 아울바이오 글루카곤 유사 펩타이드 1 작용제 함유 제어방출 미립구 및 이의 제조방법
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
KR102469409B1 (ko) * 2020-08-24 2022-11-23 주식회사 메피온 색전물질 제조 방법
WO2022103966A1 (en) 2020-11-12 2022-05-19 Amgen Inc. Methods of treating heart failure by administering omecamtiv mecarbil
WO2022153262A1 (en) 2021-01-18 2022-07-21 Anton Frenkel Pharmaceutical dosage form
EP4281187A1 (en) 2021-01-20 2023-11-29 Bioentre LLC Ctla4-binding proteins and methods of treating cancer
CA3227324A1 (en) 2021-07-06 2023-01-12 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome
WO2023137161A1 (en) 2022-01-14 2023-07-20 Amgen Inc. Triple blockade of tigit, cd112r, and pd-l1
CN114588115B (zh) * 2022-04-20 2023-01-13 上海瑞凝生物科技有限公司 一种plga药物缓释微球的制备方法
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
WO2025159538A1 (ko) * 2024-01-26 2025-07-31 주식회사 아울바이오 Glp-1 ra 기반 계열 펩타이드를 포함하는 미립구, 이의 제조방법, 및 이를 포함하는 약학적 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US5271961A (en) * 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
SE512663C2 (sv) * 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
PT1158014E (pt) * 1998-12-15 2005-04-29 Takeda Pharmaceutical Processo para a producao de poliesteres biodegradaveis
ES2266187T3 (es) * 2000-03-24 2007-03-01 Genentech, Inc. Uso de la insulina para el tratamiento de trastornos del cartilago.
US7087246B2 (en) * 2000-06-27 2006-08-08 Mi Tech Company Limited Controlled release preparation of insulin and its method
JP2004516263A (ja) * 2000-12-21 2004-06-03 ネクター セラピューティクス 疎水性活性剤を含有するマイクロ粒子の製造のための誘発相転移法
JP2003212758A (ja) * 2001-03-16 2003-07-30 Takeda Chem Ind Ltd 徐放性製剤の製造法
US20040121008A1 (en) * 2001-03-16 2004-06-24 Keiko Shiraishi Process for producing sustained release preparation
KR100566573B1 (ko) * 2002-04-13 2006-03-31 주식회사 펩트론 Ｌｈｒｈ 동족체를 함유하는 서방성 미립구의 제조방법
US8871269B2 (en) * 2003-07-15 2014-10-28 Evonik Corporation Method for the preparation of controlled release formulations
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
PT2409707E (pt) * 2004-04-15 2015-04-08 Amylin Pharmaceuticals Llc Dispositivo de libertação prolongada a base de polímero
KR100805208B1 (ko) * 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법

Also Published As

Publication number Publication date
JP5302952B2 (ja) 2013-10-02
KR101034888B1 (ko) 2011-05-17
IL201523A0 (en) 2010-05-31
KR20110044192A (ko) 2011-04-28
BRPI0810140A2 (pt) 2014-10-29
CO6241098A2 (es) 2011-01-20
CN101657190A (zh) 2010-02-24
EP2139458A1 (en) 2010-01-06
US20100129459A1 (en) 2010-05-27
KR20080094616A (ko) 2008-10-23
AU2008241699B2 (en) 2011-02-03
RU2009142608A (ru) 2011-05-27
JP2010524924A (ja) 2010-07-22
NZ580700A (en) 2012-01-12
CA2683698C (en) 2013-09-10
RU2422134C1 (ru) 2011-06-27
CA2683698A1 (en) 2008-10-30
US8282990B2 (en) 2012-10-09
AU2008241699A1 (en) 2008-10-30
WO2008130158A1 (en) 2008-10-30
CN101657190B (zh) 2013-09-11
EP2139458A4 (en) 2013-01-23

Similar Documents

Publication Publication Date Title
MX2009011275A (es) Una composicion de microesferas biodegradables adecuadas para la liberacion controlada de peptido de control de la glucosa y formulacion de la misma.
WO2010024615A3 (ko) 용매교류증발법에 의한 서방출성 미립구의 제조방법
WO2005016262A3 (en) Methods for administering aripiprazole
EP3895699A3 (en) Pharmaceutical compositions comprising iron oxy-hydroxide
IL192104A (en) Formulation suitable for subcutaneous administration containing molecules of ctla4ig, sugar and liquid liquid pharmacist acceptable and its use in drug preparation
IL195931A0 (en) Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and methods for its production
MX2008012731A (es) Tabletas de paracetamol de liberacion rapida.
BR0107874A (pt) Implante farmacêutico para controlavelmente liberar uma droga, método para controlavelmente liberar uma droga em um indivìduo, e, método para preparar o implante
WO2006125819A3 (fr) Forme medicamenteuse orale, microparticulaire, anti-mesusage
DE602008002073D1 (de) Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung
WO2009114614A3 (en) Compositions and methods for controlled delivery of inhibitory ribonucleic acids
NZ610701A (en) Once daily formulation of lacosamide
ZA200900929B (en) Microparticles based on an amphiphilic copolymer and on active ingredient(s) with modified release and pharmaceutical formulations containing same
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2006078811A3 (en) Pharmaceutical formulations and methods of use
JP2010518086A5 (es)
WO2014106116A8 (en) Therapeutic compositions comprising antibodies
WO2008084504A3 (en) Pharmaceutical compositions of angiotensin ii receptor blockers
WO2010027404A3 (en) Stable formulation comprising therapeutic polypeptides for oral administration
WO2012053785A3 (ko) 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛
IL173965A (en) Peptide compounds, pharmaceutical preparations containing them, uses and methods in vitro and ex vivo to activate a thrombopoietin receptor in the cell
WO2012092486A3 (en) Modified release benzimidazole formulations
WO2001013898A3 (en) Pharmaceutical formulations with different release times
WO2012172433A3 (en) A sustained -release composition containing a melanocortin receptor ligand as the active ingredient
GEP20125636B (en) Slow-release formulation based on glycogen and alginate association

Legal Events

Date Code Title Description
FG Grant or registration